论文部分内容阅读
Ceftibuten(SCH39720)是一种口服头孢菌素,对绝大部分肠杆菌属、产β—内酰胺酶的流感嗜血菌、脑膜炎奈瑟氏球菌、淋病奈瑟氏球菌、粘膜炎莫拉氏菌、青霉素敏感肺炎球菌、β—溶血性链球菌有活性。药代动力学数据表明每日一次口服Ceftibuten能够对治疗细菌性支气管炎有效。本文将日服一次Ceftibuten400mg与服用头孢克罗治疗支气管炎的安全性和疗效作一比较。从门诊和住院急性支气管炎病人中,挑选符合条件的病人进行比较试验。对于仅仅作72h有效抗生素的治疗,对β—内酰胺类发生急性过敏,血清肌酐≥170μmol/L,SGOT或SGPT3倍常量,血清胆红素≥34μmol/L,或中性粒细胞减少(≤1.0×10~9中性粒细胞/L)的病人均排除。
Ceftibuten (SCH39720) is an oral cephalosporin that is active against most Enterobacteriaceae, β-lactamase-producing Haemophilus influenzae, Neisseria meningitidis, Neisseria gonorrhoeae, Bacteria, penicillin-sensitive pneumococcal, β-hemolytic streptococcus activity. Pharmacokinetic data indicate that daily oral Ceftibuten can be effective in the treatment of bacterial bronchitis. This article will be served once Ceftibuten 400mg and taking cefaclor treatment of bronchitis safety and efficacy for a comparison. Outpatients and hospitalized patients with acute bronchitis, the selection of eligible patients for comparative trials. Acute hypersensitivity to [beta] -lactams, serum creatinine ≧ 170 μmol / L, SGT or SGPT ≧ 3, serum bilirubin ≧ 34 μmol / L, or neutropenia (≤1.0) for treatment with effective 72 h antibiotics only × 10 ~ 9 neutrophils / L) patients were excluded.